Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 22,10:00-12:15
Organoid and Biochip Session
Stay tuned
10:00-10:05 Opening Remarks
Qin Liang:General Manager, Shanghai Science & Technology Investment Co.Ltd.
10:05-10:20 Practical Challenges and Forward-Looking Perspectives on Organoid Applications in Toxicology
Zhang Leshuai:Professor and Associate Dean, School of Life Sciences, Soochow University
10:20-10:35 From Biomimetic Organoids to Virtual Organs: Building the Data Infrastructure for Drug Discovery in the AI Era
Wu Di:CEO, iOrganTech
10:35-10:50 Organoid + AI Enabling the Development of Innovative Targeted Therapeutics
Zhang Haisheng:Founder & CEO, Signet Therapeutics
10:50-11:05 3D Bio Intelligence: A Next-Generation Multimodal AI Engine for Drug Development Based on High-Throughput Organ-on-a-Chip
Ye Sen:Head of Scientific Affairs & Innovation, Xellar Biosystems
11:05-11:20 Toward Next-Generation In vitro Efficacy & Toxicity Platforms
HAN DONGWOOK:Head of Organoid Platform, ChemPartner
11:20-12:15 Roundtable:Rooted Deep, Growing Tall: Real-World Pathways and the Commercial Logic of Organoid Technology Industrialization
Wan Fei (Moderator):Co-Founder, iOrganTech
Wu Di: CEO, iOrganTech
Xiong Yao:Director of In Vivo Pharmacology, Innovent Biologics
Xu Yuzhou:Executive Director, ChemPartner
Ye Sen:Head of Scientific Affairs & Innovation, Xellar Biosystems
Zhang Haisheng:Founder & CEO, Signet Therapeutics
Zhang Leshuai:Professor and Associate Dean, School of Life Sciences, Soochow University
Zhou Yan:Deputy General Manager, Investment Promotion Service Center, Shanghai Pudong Development (Group) Co.,Ltd.